A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
Jazz Pharmaceuticals
Merck Sharp & Dohme LLC
Leap Therapeutics, Inc.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
University of Nebraska
Novo Nordisk A/S
AIO-Studien-gGmbH
The Christie NHS Foundation Trust
Bayer
M.D. Anderson Cancer Center
Senhwa Biosciences, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Eli Lilly and Company
PCI Biotech AS
Center Eugene Marquis
Hannover Medical School
University College, London
Dana-Farber Cancer Institute